Bath & Body Works, Inc. (NYSE:BBWI) Shares Sold by Graphene Investments SAS

Graphene Investments SAS lowered its position in shares of Bath & Body Works, Inc. (NYSE:BBWI - Free Report) by 15.9% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 78,400 shares of the company's stock after selling 14,800 shares during the period. Bath & Body Works comprises about 2.1% of Graphene Investments SAS's holdings, making the stock its 16th largest position. Graphene Investments SAS's holdings in Bath & Body Works were worth $3,040,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. FMR LLC increased its position in Bath & Body Works by 17,496.5% in the 3rd quarter. FMR LLC now owns 2,516,127 shares of the company's stock valued at $80,315,000 after acquiring an additional 2,501,828 shares during the period. KBC Group NV boosted its holdings in Bath & Body Works by 9,023.5% in the 3rd quarter. KBC Group NV now owns 1,701,813 shares of the company's stock valued at $54,322,000 after purchasing an additional 1,683,160 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in Bath & Body Works in the 3rd quarter valued at approximately $50,483,000. Assenagon Asset Management S.A. boosted its holdings in Bath & Body Works by 723.4% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,167,554 shares of the company's stock valued at $37,268,000 after purchasing an additional 1,025,757 shares in the last quarter. Finally, Senvest Management LLC purchased a new stake in Bath & Body Works in the 3rd quarter valued at approximately $30,537,000. Institutional investors and hedge funds own 95.14% of the company's stock.

Bath & Body Works Stock Down 0.4 %

Shares of Bath & Body Works stock traded down $0.15 during trading on Tuesday, hitting $35.33. 2,119,771 shares of the company were exchanged, compared to its average volume of 2,957,188. The firm has a 50 day moving average price of $37.71 and a 200 day moving average price of $33.65. The stock has a market capitalization of $7.65 billion, a price-to-earnings ratio of 8.60, a P/E/G ratio of 0.90 and a beta of 1.83. Bath & Body Works, Inc. has a fifty-two week low of $26.20 and a fifty-two week high of $52.99.

Bath & Body Works (NYSE:BBWI - Get Free Report) last issued its quarterly earnings results on Monday, November 25th. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of $0.46 by $0.03. The company had revenue of $1.61 billion during the quarter, compared to the consensus estimate of $1.58 billion. Bath & Body Works had a negative return on equity of 44.03% and a net margin of 12.43%. Bath & Body Works's revenue was up 3.1% on a year-over-year basis. During the same period in the previous year, the firm posted $0.48 EPS. Analysts predict that Bath & Body Works, Inc. will post 3.26 earnings per share for the current year.

Bath & Body Works Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 21st will be issued a $0.20 dividend. The ex-dividend date is Friday, February 21st. This represents a $0.80 annualized dividend and a yield of 2.26%. Bath & Body Works's dividend payout ratio (DPR) is presently 19.51%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on BBWI. Wells Fargo & Company raised Bath & Body Works from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $42.00 to $48.00 in a report on Friday, January 10th. Morgan Stanley lowered their price objective on Bath & Body Works from $51.00 to $48.00 and set an "overweight" rating on the stock in a report on Thursday, November 21st. Barclays lifted their price objective on Bath & Body Works from $28.00 to $34.00 and gave the company an "underweight" rating in a report on Tuesday, November 26th. Piper Sandler boosted their price target on Bath & Body Works from $36.00 to $39.00 and gave the stock a "neutral" rating in a research note on Monday, January 6th. Finally, Argus reissued a "hold" rating on shares of Bath & Body Works in a research note on Friday, January 10th. One research analyst has rated the stock with a sell rating, six have issued a hold rating and ten have issued a buy rating to the stock. Based on data from MarketBeat.com, Bath & Body Works has an average rating of "Moderate Buy" and a consensus price target of $43.19.

About Bath & Body Works

Bath & Body Works, Inc is a specialty retailers and home to America's Favorite Fragrances, offering a breadth of exclusive fragrances for the body and home, including the selling collections for fine fragrance mist, body lotion and body cream, 3-wick candles, home fragrance diffusers and liquid hand soap.